Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 1/2 3Phase 3 2Phase 1 2

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Ovarian Neoplasms 9Neoplasms 2Fallopian Tube Neoplasms 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Recurrence 1Prostatic Neoplasms, Castration-Resistant 1Metastatic Castration-sensitive Prostate Cancer 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Glioblastoma 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1Biliary Tract Neoplasms 1

Interventions

Paclitaxel 45Carboplatin 33Bevacizumab 17liposomal doxorubicin 15Topotecan 12Taxes 10Gemcitabine 10Drug Therapy 6Cisplatin 6rucaparib 5mirvetuximab soravtansine 5Docetaxel 5Immunoglobulin G 4Doxorubicin 4Disulfides 4trebananib 3pembrolizumab 3olaparib 3Saline Solution 3Neoadjuvant Therapy 3Hyperthermic Intraperitoneal Chemotherapy 3Dexamethasone 3CP protocol 3niraparib 2cediranib 2Tamoxifen 2Specimen Handling 2Letrozole 2Glucose 2Cytoreduction Surgical Procedures 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Fallopian Tube Neoplasms × niraparib × Clear all
NCT06915025 2026-05-04

OVATION-3

Imunon

Phase 3 Recruiting
500 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05009082 2025-09-10

Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer

AGO Study Group

Phase 3 Recruiting
970 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡